We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Ingevity (NGVT) Up 2.4% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Ingevity Corporation (NGVT - Free Report) . Shares have added about 2.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Ingevity Corporation due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Ingevity’s Q2 Earnings & Revenues Beat Estimates
Ingevity recorded a profit (attributable to stockholders) of $46.7 million or $1.10 per share in second-quarter 2018, surging roughly 45% from $32.1 million or 76 cents a year ago.
Barring one-time items, earnings came in at $1.12 per share in the quarter, surpassing the Zacks Consensus Estimate of 99 cents.
The company’s revenues rose roughly 19% year over year to $308.6 million in the quarter, squeaking past the Zacks Consensus Estimate of $308.2 million.
Adjusted EBITDA climbed roughly 33% year over year to $89.4 million in the quarter.
The company gained from strong organic growth, contributions of Georgia-Pacific pine chemicals acquisition, excellent commercial and operational execution and strong productivity.
Segment Review
Revenues from the Performance Chemicals division jumped around 24% year over year to $212.5 million in the quarter. Revenues were driven by sales growth in oilfield industry on the back of higher U.S. drilling and production, along with the strong adoption of the company’s pavement technologies. The buyout of Georgia-Pacific pine chemicals business also supported the growth.
Revenues from the Performance Materials unit went up around 7% to $96.1 million. The growth was supported by strong volumes of the company’s solutions geared to meet the U.S. EPA Tier 3 and California LEV III emission regulations.
Balance Sheet
Ingevity ended the quarter with cash and cash equivalents of $83 million, a more than two-fold year over year increase. Long-term debt was $729.5 million, up around 57%.
Outlook
Ingevity remains optimistic about 2018 as it is witnessing the benefits of improving market conditions for its basic materials and high-value added technologies. The company increased the mid-point and narrowed the range for its 2018 guidance for adjusted EBITDA to $302-$314 million from $293-$307 million. The company backed its sales guidance of between $1.10 billion and $1.13 billion for the year.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
At this time, Ingevity Corporation has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for growth investors than momentum investors.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Ingevity Corporation has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Ingevity (NGVT) Up 2.4% Since Last Earnings Report?
A month has gone by since the last earnings report for Ingevity Corporation (NGVT - Free Report) . Shares have added about 2.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Ingevity Corporation due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Ingevity’s Q2 Earnings & Revenues Beat Estimates
Ingevity recorded a profit (attributable to stockholders) of $46.7 million or $1.10 per share in second-quarter 2018, surging roughly 45% from $32.1 million or 76 cents a year ago.
Barring one-time items, earnings came in at $1.12 per share in the quarter, surpassing the Zacks Consensus Estimate of 99 cents.
The company’s revenues rose roughly 19% year over year to $308.6 million in the quarter, squeaking past the Zacks Consensus Estimate of $308.2 million.
Adjusted EBITDA climbed roughly 33% year over year to $89.4 million in the quarter.
The company gained from strong organic growth, contributions of Georgia-Pacific pine chemicals acquisition, excellent commercial and operational execution and strong productivity.
Segment Review
Revenues from the Performance Chemicals division jumped around 24% year over year to $212.5 million in the quarter. Revenues were driven by sales growth in oilfield industry on the back of higher U.S. drilling and production, along with the strong adoption of the company’s pavement technologies. The buyout of Georgia-Pacific pine chemicals business also supported the growth.
Revenues from the Performance Materials unit went up around 7% to $96.1 million. The growth was supported by strong volumes of the company’s solutions geared to meet the U.S. EPA Tier 3 and California LEV III emission regulations.
Balance Sheet
Ingevity ended the quarter with cash and cash equivalents of $83 million, a more than two-fold year over year increase. Long-term debt was $729.5 million, up around 57%.
Outlook
Ingevity remains optimistic about 2018 as it is witnessing the benefits of improving market conditions for its basic materials and high-value added technologies. The company increased the mid-point and narrowed the range for its 2018 guidance for adjusted EBITDA to $302-$314 million from $293-$307 million. The company backed its sales guidance of between $1.10 billion and $1.13 billion for the year.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
At this time, Ingevity Corporation has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate that the stock is more suitable for growth investors than momentum investors.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Ingevity Corporation has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.